Hantavirus Pulmonary Syndrome

Acute respiratory illness in humans caused by the SIN NOMBRE VIRUS whose primary rodent reservoir is the deer mouse Peromyscus maniculatus. First identified in the southwestern United States, this syndrome is characterized most commonly by fever, myalgias, headache, cough, and rapid respiratory failure.

Also Known As:

Networked: 77 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infections
2.	Hemorrhagic Fever with Renal Syndrome (HFRS)
3.	Paramyxoviridae Infections (Parainfluenza)
4.	Communicable Diseases (Infectious Diseases)
5.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)

Experts

1.	Hooper, Jay W: 6 articles (01/2015 - 01/2012)
2.	Ballantyne, John: 5 articles (01/2015 - 01/2012)
3.	Ksiazek, T G: 4 articles (09/2003 - 03/2000)
4.	Royals, Michael: 3 articles (01/2015 - 01/2014)
5.	Josleyn, Matthew: 3 articles (01/2014 - 01/2012)
6.	Mills, James N: 3 articles (01/2012 - 06/2002)
7.	Peters, C J: 3 articles (02/2002 - 03/2000)
8.	Falzarano, Darryl: 2 articles (01/2021 - 10/2013)
9.	Safronetz, David: 2 articles (01/2021 - 10/2013)
10.	García, Marina: 2 articles (01/2019 - 01/2017)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hantavirus Pulmonary Syndrome:

1.	RNA (Ribonucleic Acid)IBA 10/01/1994 - "Detection of Muerto Canyon virus RNA in peripheral blood mononuclear cells from patients with hantavirus pulmonary syndrome." 01/01/2022 - "FPV is also effective against other RNA respiratory viruses and may be a candidate for the treatment of serious infections caused by human rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza viruses and hantavirus pulmonary syndrome." 10/01/1994 - "To determine if Muerto Canyon Virus (MCV) RNA is present in the peripheral blood of patients with hantavirus pulmonary syndrome, a reverse transcriptase-polymerase chain reaction (RT-PCR) assay for MCV RNA was used on blood samples from 20 seropositive case-patients. " 12/01/1993 - "Utilization of autopsy RNA for the synthesis of the nucleocapsid antigen of a newly recognized virus associated with hantavirus pulmonary syndrome." 01/01/2001 - "Hantavirus-specific IgM, or positive immunohistochemical analysis for hantavirus antigen, or positive reverse transcription-polymerase chain reaction results for hantavirus RNA were used to confirm nine of these cases; eight were hantavirus pulmonary syndrome (HPS), and one was mild hantavirus disease. "
2.	Antiviral Agents (Antivirals)IBA 10/01/2013 - "Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome." 01/01/2015 - "Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure."
3.	favipiravirIBA 10/01/2013 - "Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome."
4.	feralIBA 01/01/1998 - "As the technology to differentiate virus species has improved, it has become clear that there are numerous potentially hazardous viruses capable of causing HFRS or hantavirus pulmonary syndrome (HPS) within the feral rodent population. "
5.	AntibodiesIBA 03/01/2004 - "We conducted a peridomestic study of small mammals to evaluate the relationships between the presence of rodents with antibodies to Andes virus confirmed human cases of hantavirus pulmonary syndrome in southcentral Chile. " 01/01/2021 - "Polyclonal alpaca antibodies protect against hantavirus pulmonary syndrome in a lethal Syrian hamster model." 08/01/2008 - "This is the first report of the presence of antibodies to a hantavirus among rodents from Rio de Janeiro and suggests the possibility of human cases of hantavirus pulmonary syndrome (HPS) in that state, although no case has yet been reported." 01/01/2005 - "Following the occurrence of the first laboratory-confirmed cases of hantavirus pulmonary syndrome (HPS) in Maranhao State, Brazil, rodents were trapped and rodent materials screened by ELISA for antibodies to Sin Nombre and Andes hantaviruses. " 07/01/2000 - "[Prevalence of anti-hantavirus antibodies in health care personnel in direct contact with patients with hantavirus pulmonary syndrome in Temuco, Chile 1997 to 1999]."
6.	Immunoglobulin G (IgG)IBA 12/01/2010 - "To confirm circulation of Anajatuba virus in Maranhao, Brazil, we conducted a serologic survey (immunoglobulin G ELISA) and phylogenetic studies (nucleocapsid gene sequences) of hantaviruses from wild rodents and persons with hantavirus pulmonary syndrome. " 01/01/2021 - "Here, we sought to evaluate the use of unique camelid-based IgG antibodies to prevent lethal hantavirus pulmonary syndrome (HPS) in Syrian hamsters. " 11/26/2014 - "DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome." 01/01/1998 - "An additional two cases in healthy children were studied: one, a breast-fed 15-month-old whose mother died of suspected hantavirus pulmonary syndrome (HPS) 8 months previously, had hantavirus IgG (> 1:6400); a second, whose mother survived HPS during month three of pregnancy, apparently had maternal antibodies no longer detectable 1 year after birth." 05/01/2001 - "Hantavirus pulmonary syndrome was confirmed by the detection of immunoglobulin M and immunoglobulin G antibodies to the Sin Nombre virus (SNV) in her sera and by the demonstration of SNV genomic sequences in her lung tissue. "
7.	Ribavirin (Virazole)FDA LinkGeneric 02/01/2002 - "Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome." 11/08/2013 - "Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus." 02/01/2002 - "To provide a potentially therapeutic intervention and to collect clinical and laboratory data during an outbreak of hantavirus pulmonary syndrome (HPS), 140 patients from the United States with suspected HPS were enrolled for investigational intravenous ribavirin treatment. " 01/01/1999 - "Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. " 01/01/1999 - "Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. "
8.	VaccinesIBA 10/01/2004 - "An Andes virus gene-based hantavirus pulmonary syndrome vaccine is currently under study. " 01/01/2019 - "The robust replication-competent rVSVs, bearing HTNV and DOBV Gn/Gc, reported herein may also have utility as vaccines.IMPORTANCE Human hantavirus infections cause hantavirus pulmonary syndrome in the Americas and hemorrhagic fever with renal syndrome (HFRS) in Eurasia. " 09/13/2013 - "A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS)."
9.	2-methylfuranIBA 03/01/2001 - "Most human cases of hantavirus pulmonary syndrome are acquired in the peridomestic environment, yet studies of the ecology and infection dynamics in the reservoir host, the deer mouse (Peromyscus maniculatus), have focused on sylvan populations. " 01/01/2017 - "Hantavirus pulmonary syndrome is a severe cardio pulmonary disease transmitted to humans by sylvan rodents found in natural and rural environments. "
10.	GoldIBA 01/01/2019 - "This study is designed to describe fatal hantavirus pulmonary syndrome (HPS) cases confirmed by serology and molecular analysis, where a seroprevalence survey was conducted in the gold mining regions of the state of Mato Grosso, in the official Amazon region, Brazil. " 01/01/2019 - "Malaria and Hantavirus Pulmonary Syndrome in Gold Mining in the Amazon Region, Brazil."

Therapies and Procedures

1.	Critical Care (Surgical Intensive Care) 05/19/2021 - "The patient did not require intensive care-as it is commonplace during hantavirus pulmonary syndrome-and he had a good outcome. " 03/01/2014 - "Eight case-patients experienced hantavirus pulmonary syndrome, of whom 5 required intensive care with ventilatory support and 3 died. " 02/01/1998 - "Hantavirus pulmonary syndrome: implications for critical care nurses."
2.	Therapeutics 02/01/1998 - "To describe our experience with the use of extracorporeal membrane oxygenation (ECMO) as a rescue therapy in adult patients with severe cardiopulmonary failure from Hantavirus pulmonary syndrome. " 01/01/2005 - "No specific therapy is currently available against hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome. " 02/01/1998 - "Our experience suggests that ECMO is a beneficial therapy for patients critically ill with Hantavirus pulmonary syndrome." 09/01/2015 - "To alert clinicians to the climatic conditions that can precipitate outbreaks of the rodent-borne infectious diseases most often associated with flooding disasters, leptospirosis (LS), and the Hantavirus-caused diseases, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS); to describe the epidemiology and presenting clinical manifestations and outcomes of these rodent-borne infectious diseases; and to recommend both prophylactic therapies and effective control and prevention strategies for rodent-borne infectious diseases. " 01/01/2015 - "To alert clinicians to the climatic conditions that can precipitate outbreaks of the rodent-borne infectious diseases most often associated with flooding disasters, leptospirosis (LS), and the Hantavirus-caused diseases, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS); to describe the epidemiology and presenting clinical manifestations and outcomes of these rodent-borne infectious diseases; and to recommend both prophylactic therapies and effective control and prevention strategies for rodent-borne infectious diseases. "
3.	Extracorporeal Membrane Oxygenation 07/01/2005 - "[Addition of an arterio-venous shunt during veno-arterial extracorporeal life support in a patient with Hantavirus pulmonary syndrome]." 02/01/1998 - "Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation." 02/01/1998 - "Severe Hantavirus pulmonary syndrome: a new indication for extracorporeal life support?" 02/01/1998 - "To describe our experience with the use of extracorporeal membrane oxygenation (ECMO) as a rescue therapy in adult patients with severe cardiopulmonary failure from Hantavirus pulmonary syndrome. "
4.	Artificial Respiration (Mechanical Ventilation) 05/01/2006 - "The medical records of 27 patients with hantavirus pulmonary syndrome were analyzed according to the need for invasive mechanical ventilation in relation to the following data up on hospital admission: age, gender, fever, cough, dyspnea, systolic arterial blood pressure, heart rate, levels of hemoglobin, hematocrit, leukocytes, lymphocytes, platelets, creatinine and arterial blood gases. "
5.	Continuous Renal Replacement Therapy 04/01/2006 - "Reported here are two cases of hantavirus pulmonary syndrome caused by Puumala virus infection, which rapidly resolved after initiation of corticosteroid treatment combined with continuous veno-venous hemodiafiltration. " 04/01/2006 - "Corticosteroids combined with continuous veno-venous hemodiafiltration for treatment of hantavirus pulmonary syndrome caused by Puumala virus infection."